ArticleThe European respiratory journal2020
Cyclosporine: an old weapon in the fight against coronaviruses.
Article in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- How Effective are Nanotechnology-Based Therapeutics to Treat Autoimmune Diseases.International journal of nanomedicine · 2026Review
- Unveiling hepatic Krüppel-like factor 15 as the key regulator of cyclosporine A metabolism and adverse effects.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Effect of cyclosporin A on respiratory viral replication in fully differentiated ex vivo human airway epithelia.Pharmacology research & perspectives · 2024Article
- An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro.Pharmaceutics · 2023Article
- Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID-19.Diabetes/metabolism research and reviews · 2022Review
- An inductive graph neural network model for compound-protein interaction prediction based on a homogeneous graph.Briefings in bioinformatics · 2022Review
- Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.Microbiology spectrum · 2022Article
- Targeting cathepsins: A potential link between COVID-19 and associated neurological manifestations.Heliyon · 2021Article
- Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2.Open forum infectious diseases · 2021Article
- Evaluation of the Pharmacologic Treatment of COVID-19 Pandemic in Iraq.Current pharmacology reports · 2021Review
- Article
- Therapeutic Strategies in the Management of COVID-19.Frontiers in molecular biosciences · 2020Review
- Mitochondrial Ion Channels of the Inner Membrane and Their Regulation in Cell Death Signaling.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.